Pediatric Radiology

, Volume 33, Issue 6, pp 373–377

SQUID biosusceptometry in the measurement of hepatic iron

Invited Commentary

Abstract

Individuals with primary or secondary abnormalities of iron metabolism, such as hereditary hemochromatosis and transfusional iron loading, may develop potentially lethal systemic iron overload. Over time, this excess iron is progressively deposited in the liver, heart, pancreas, and other organs, resulting in cirrhosis, heart disease, diabetes and other disorders. Unless treated, death usually results from cardiac failure. The amount of iron in the liver is the best indicator of the amount of iron in the whole body. At present, the only sure way to measure the amount of iron in the liver is to remove a sample of the liver by biopsy. Iron stored in the liver can be magnetized to a small degree when placed in a magnetic field. The amount of magnetization is measured by our instrument, called a superconducting quantum interference device (SQUID) susceptometer. In patients with iron overload, our previous studies have shown that magnetic measurements of liver iron in patients with iron overload are quantitatively equivalent to biochemical determinations on tissue obtained by biopsy. The safety, ease, rapidity, and comfort of magnetic measurements make frequent, serial studies technically feasible and practically acceptable to patients.

Keywords

Iron overload Non-invasive measurement Magnetic susceptibility SQUID 

References

  1. 1.
    Sheth S, Brittenham GM (2000) Genetic disorders affecting proteins of iron metabolism: clinical implications. Annu Rev Med 51:443–464CrossRefPubMedGoogle Scholar
  2. 2.
    Farrell DE, Tripp JH, Zanzucchi PE, et al (1980) Magnetic measurement of human iron stores. IEEE Trans Magnetics 16:818–823Google Scholar
  3. 3.
    Farrell DE, Tripp JH, Zanzucchi PE, et al (1981) An application of superconductivity to medical diagnostics. Appl Phys Commun 1:1–7Google Scholar
  4. 4.
    Brittenham GM, Farrell DE, Harris JW, et al (1982) Magnetic-susceptibility measurement of human iron stores. N Engl J Med 307:1671–1675PubMedGoogle Scholar
  5. 5.
    Farrell DE (1983) Assessment of iron in human tissue: the magnetic biopsy. In: Williamson SJ, Romani GL, Kaufman L (eds) Biomagnetism: an interdisciplinary approach. Plenum Press, New York, p 483Google Scholar
  6. 6.
    Fischer R (1998) Liver iron susceptometry. In: Andra W, Nowak H (eds) Magnetism in medicine: a handbook. Wiley-VCH, Berlin, pp 286–301Google Scholar
  7. 7.
    Brittenham GM (1988) Noninvasive methods for the early detection of hereditary hemochromatosis. Ann N Y Acad Sci 526:199–208PubMedGoogle Scholar
  8. 8.
    Brittenham GM, Cohen AR, McLaren CE, et al (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 42:81–85PubMedGoogle Scholar
  9. 9.
    Fischer R, Tiemann CD, Engelhardt R, et al (1999) Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. Am J Hematol 60:289–299CrossRefPubMedGoogle Scholar
  10. 10.
    Brittenham GM, Sheth S, Allen CJ, et al (2001) Non-invasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol 38 [Suppl 1]:37–56Google Scholar
  11. 11.
    Nielsen P, Fischer R, Engelhardt R, et al (1995) Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. Br J Haematol 91:827–833PubMedGoogle Scholar
  12. 12.
    Nielsen P, Engelhardt R, Duerken M, et al (2000) Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. Transfus Sci 23:257–258CrossRefPubMedGoogle Scholar
  13. 13.
    Paulson DN, Fagaly RL, Toussaint RM, et al (1991) Biomagnetic susceptometer with SQUID Instrumentation. IEEE Trans Magnetics 27:3249–3252CrossRefGoogle Scholar
  14. 14.
    Piga A, Galanello R, Cappellini MD, et al (2002) Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy (abstract). Blood 100[Suppl1]:5aGoogle Scholar
  15. 15.
    Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89:739–761PubMedGoogle Scholar
  16. 16.
    Olivieri NF, Brittenham GM, Matsui D,et al (1995) Iron chelation therapy with oral deferiprone (L1) in patients with thalassemia major. N Engl J Med 332:918–922CrossRefPubMedGoogle Scholar
  17. 17.
    Brittenham GM, Badman DG (2003) Noninvasive measurement of iron: report of an NIDDK Workshop. Blood 101:15–19Google Scholar
  18. 18.
    Kumar S, Avrin WF (1999) A low-cost biomagnetic susceptometer based on room-temperature sensors. In: Yoshimoto T, Kotani M, Kuriki S, Karibe H, Nakasato N (eds) Recent advances in biomagnetism. Proceedings of the 11th International Conference on Biomagnetism. Tohoku University Press, Sendai, pp 1160–1109Google Scholar
  19. 19.
    Wang ZJ, Li S, Haselgrove JC (1999) Magnetic resonance imaging measurement of volume magnetic susceptibility using a boundary condition. J Magn Reson 140:477–481CrossRefPubMedGoogle Scholar
  20. 20.
    Farrell DE, Allen CJ, Arendt PN, et al (1999) High Tc susceptometry. Am Phys Soc Abstr VC07.03Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Department of PediatricsColumbia University College of Physicians and Surgeons, Harkness Pavilion, Room HP570New YorkUSA

Personalised recommendations